Other
12 Authors
- True L,
- Sun H,
- Roudier MP,
- Li S,
- Xin L,
- Jia D,
- Kwon O,
- Lee JK,
- Creighton CJ,
- Zhou Z,
- Lin DW,
- Morrissey C
| First Author | Zhou Z | Year | 2023 |
| Journal | Oncogene | Volume | 42 |
| Issue | 32 | Pages | 2428-2438 |
| PubMed ID | 37400528 | Mgi Jnum | J:338796 |
| Mgi Id | MGI:7514682 | Doi | 10.1038/s41388-023-02759-7 |
| Citation | Zhou Z, et al. (2023) Androgen-regulated stromal complement component 7 (C7) suppresses prostate cancer growth. Oncogene |
| abstractText | The complement system is a major component of the innate immune system that works through the cytolytic effect of the membrane attack complex (MAC). Complement component 7 (C7) is essential for MAC assembly and its precisely regulated expression level is crucial for the cytolytic activity of MAC. We show that C7 is specifically expressed by the stromal cells in both mouse and human prostates. The expression level of C7 inversely correlates with clinical outcomes in prostate cancer. C7 is positively regulated by androgen signaling in the mouse prostate stromal cells. The androgen receptor directly transcriptionally regulates the mouse and human C7. Increasing C7 expression in the C57Bl/6 syngeneic RM-1 and Pten-Kras allografts suppresses tumor growth in vivo. Conversely, C7 haploinsufficiency promotes tumor growth in the transgenic adenocarcinoma of the mouse prostate (TRAMP) model. Interestingly, replenishing C7 in androgen-sensitive Pten-Kras tumors during androgen depletion only slightly enhances cellular apoptosis, highlighting the diverse mechanisms employed by tumors to counteract complement activity. Collectively, our research indicates that augmenting complement activity could be a promising therapeutic approach to impede the development of castration resistance in prostate cancer. |
